Phathom Pharmaceuticals (PHAT)
(Delayed Data from NSDQ)
$9.18 USD
+0.08 (0.88%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $9.19 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Phathom Pharmaceuticals, Inc. [PHAT]
Reports for Purchase
Showing records 1 - 7 ( 7 total )
Company: Phathom Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Voquezna in Erosive GERD Off to the Races-Non-Erosive GERD Near-Term PDUFA; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Phathom Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Near-Term Combined Launch in Erosive GERD and H. Pylori Assert Voquezna; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Phathom Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Voquezna FDA Approval Sets New Stage in Erosive GERD and Beyond-First Innovation in Decades; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Phathom Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Vonoprazan Stability-Looking to November PDUFA, Potential 4Q23 Launch; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Phathom Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Novel GERD Therapy With Potential Commercial Launches 4Q23; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Phathom Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Novel PCAB Approach Turns New Page for GERD Therapy; Initiating With Buy Rating and $28 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Phathom Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
|